日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Neoadjuvant PARP inhibitor scheduling in BRCA1 and BRCA2 related breast cancer: PARTNER, a randomized phase II/III trial.

BRCA1 和 BRCA2 相关乳腺癌的新辅助 PARP 抑制剂治疗方案:PARTNER,一项随机 II/III 期试验

Abraham Jean E, O'Connor Lenka Oplustil, Grybowicz Louise, Alba Karen Pinilla, Dayimu Alimu, Demiris Nikolaos, Harvey Caron, Drewett Lynsey M, Lucey Rebecca, Fulton Alexander, Roberts Anne N, Worley Joanna R, Chhabra Ms Anita, Qian Wendi, Brown Jessica, Hardy Richard, Vallier Anne-Laure, Chan Steve, Cidon Maria Esther Una, Sherwin Elizabeth, Chakrabarti Amitabha, Sadler Claire, Barnes Jen, Persic Mojca, Smith Sarah, Raj Sanjay, Borley Annabel, Braybrooke Jeremy P, Staples Emma, Scott Lucy C, Palmer Cheryl A, Moody Margaret, Churn Mark J, Pilger Domenic, Zagnoli-Vieira Guido, Wijnhoven Paul W G, Mukesh Mukesh B, Roylance Rebecca R, Schouten Philip C, Levitt Nicola C, McAdam Karen, Armstrong Anne C, Copson Ellen R, McMurtry Emma, Galbraith Susan, Tischkowitz Marc, Provenzano Elena, O'Connor Mark J, Earl Helena M

Management of Skin Toxicity Related to the Use of Imatinib Mesylate (STI571, Glivectrade mark) for Advanced Stage Gastrointestinal Stromal Tumours

伊马替尼甲磺酸盐(STI571,格列卫商标)治疗晚期胃肠道间质瘤相关皮肤毒性的管理

Scott, Lucy C; White, Jeff D; Reid, Robin; Cowie, Fiona